MedTrace Logo

Topical Betaxolol for the Prevention of Retinopathy of Prematurity

NCT01660620 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 23

Last updated 2013-01-03

No results posted yet for this study

Summary

We hypothesize that topical betaxolol will reduce the development of severe retinopathy of prematurity.

Conditions

  • Development of Side Effects From Betaxolol

Interventions

DRUG

Betaxolol

DRUG

topical betaxolol

given topically

Sponsors & Collaborators

  • Ohio State University

    collaborator OTHER

  • University of Minnesota

    collaborator OTHER

  • University of Oklahoma

    collaborator OTHER

  • The University of Texas Health Science Center, Houston

    collaborator OTHER

  • Smith-Kettlewell Eye Research Institute

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
32 Weeks
Max Age
32 Weeks
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-04-30
Primary Completion
2011-11-30
Completion
2011-11-30

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01660620 on ClinicalTrials.gov